Pharmafile Logo
Pharmafocus logo
Advanced Search
FDA picture

Obesity drug supported by FDA panel

February 23, 2012
Sales and Marketing FDA, Qnexa, Vivus, Xenical, obesity

Vivus’ obesity drug Qnexa has been supported by an FDA panel, two years after it was knocked back by the …

News
Lansley picture

GPs to ‘prescribe’ apps for patients

February 22, 2012
Medical Communications GPs, Lansley, NHS, apps

Family doctors in England could soon be asked to ‘prescribe’ apps to patients to help them manage their medical conditions. …

News
EMA image

EMA to open up drug evaluation process

February 22, 2012
Medical Communications, Sales and Marketing CHMP, EMA, FDA

The European Medicines Agency will publish ongoing drug evaluations in an effort to make its processes more transparent. The Agency …

News

CCGs already helping patients, says Lansley

February 22, 2012
CCGs, Lansley, NHS, NHS reform

The government has set out a number of ways in which its controversial health reforms are already benefiting patients. The …

News

Alex Gorsky named new chief executive of J&J

February 22, 2012
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alex Gorsky, J&J, JJ, Janssen, Weldon

Johnson & Johnson has named Alex Gorsky as its new chief executive, effective from 26 April. Gorsky was also nominated …

Appointment
Takeda image

Takeda’s ulcerative colitis drug gets Phase III boost

February 22, 2012
Research and Development

Takeda’s ulcerative colitis drug vedolizumab has succeeded in a late-stage trial.  The Phase III trial studied vedolizumab in 895 patients …

News

Publicis buys Chinese med comms firm

February 22, 2012
Medical Communications Publicis Life Brands Watermelon, UBS, publicis

Publicis has acquired Chinese healthcare communications firm U-Link Business Solutions (UBS), adding to its portfolio in Asia.UBS will become part …

News
Caprelsa image

Caprelsa approved in Europe for thyroid cancer

February 21, 2012
Sales and Marketing AstraZeneca, Caprelsa, FDA, RET, thyroid cancer

The European Commission has approved AstraZeneca’s thyroid cancer pill Caprelsa. Caprelsa (vandetanib) is now available in Europe for the treatment …

News
Zytiga image

Zytiga approved in Wales – for now

February 21, 2012
Sales and Marketing AWMSG, CDF, Janssen, NICE, Wales, Zytiga

Janssen’s cancer treatment Zytiga has been approved in Wales, in contrast to its rejection by NICE. The All Wales Medicines …

News
Georg Toufar

Working Life: Georg Toufar, director, Mundipharma

February 21, 2012
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Georg Toufar, Mundipharma, Working Life

Georg Toufar is director of European marketing and sales and member of the executive committee at Mundipharma International Limited (MINT).  …

Feature

Bayer eye drug succeeds in long-term study

February 21, 2012
Research and Development, Sales and Marketing Bayer, Lucentis, aflibercept, wet AMD

Bayer’s eye drug aflibercept has succeeded in a long-term study in patients with a common eye condition.  The Phase III …

News
Teva image

MHRA suspends Teva licence for levothyroxine generic

February 21, 2012
Manufacturing and Production MHRA, Numark, Teva, levothyroxine

The UK medicine regulatory authority has suspended the licence for a levothyroxine product sold by Teva on the grounds that …

News

Contract research news in brief

February 21, 2012
Research and Development Almac, GVK Biosciences and PreClinOmics/AIT, PPD, Quintiles

Our round-up of news from the contract research sector includes PPD’s sales to a private equity consortium, new clinical supply …

News

Asymchem plans additional investment in Dunhua facility

February 21, 2012
Manufacturing and Production Asymchem, China, Dunhua, manufacturing

China’s Asymchem Laboratories says it plans to invest another $12 million in its recently-opened manufacturing facility in Dunhua, Jilin province, …

News

Setback for Gilead hep C candidate

February 20, 2012
Research and Development, Sales and Marketing ELECTRON, GS-7977, Gilead, Pharmasset

Gilead’s investigational hepatitis C drug has been dealt a blow after patients suffer relapses in a mid-stage trial.  In the …

News

Shortages likely as Sandoz’s Canadian plant woes continue

February 20, 2012
Manufacturing and Production FDA, Novartis, Sandoz

Ongoing compliance problems at a plant in Canada operated by Novartis’ generics subsidiary Sandoz look set to cause supply disruptions …

News

Pfizer closes in on $545m China generics deal

February 20, 2012
Business Services, Manufacturing and Production, Research and Development, Sales and Marketing China, Hisun, Pfizer, Zhejiang, generics

Pfizer has moved a step closer to a deal with Shanghai-based Zhejiang Hisun Pharmaceutical to develop generic drugs in China.  …

News

Health Information appoints Nigel Brooksby as its deputy chairman

February 20, 2012
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, Brooksby, Health Information

Health Information, a provider of medicine adherence services in the UK, has appointed former ABPI president Nigel Brooksby as its …

Appointment
Zelboraf image

European approval for Roche’s Zelboraf

February 20, 2012
Sales and Marketing Cancer, Roche, Yervoy, Zelboraf, melanoma

Roche’s skin cancer pill Zelboraf has been given European approval to treat advanced melanoma.  Zelboraf (vemurafenib) is now available in …

News
Tyverb picture

GSK pulls Tyverb extension in Europe

February 17, 2012
Sales and Marketing GSK, Herceptin, Tyverb, Xeloda

GlaxoSmithKline has withdrawn its European application to extend the licence of its breast cancer pill Tyverb. The firm was seeking …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026